Summary The 1580 LL and BL leprosy patients in a community of 480,000 persons in South India were studied for the occurrence of dapsone-resistant My cobacterium ieprae, between March 1978 and February 1981. Patients with a BI :;;, 2 + were biopsied for mouse inoculation, even if they were improving on dapsone monotherapy. Between 89 and 116 patients per 1000 patients screened were estimated to harbour dapsone-resistant M. ieprae.
Gudiyatham Taluk of North Arcot District in Tamil Nadu, the leprosy control area of the Schieffe1in Leprosy Research and Training Centre, covers an area of approximately 1320 sq km with a population of 480,000 (1981 Census). The region is hyperendemic for leprosy, and in December 1977, 6880 patients were on the treatment register at 44 peripheral clinics within the control area. Dapsone mono therapy has been extensively used in this area since 1963, and fa irly accurate records of patients have been maintained systematically throughout this period.
The objectives of the study were: 1, to determine the number of registered patients who harbour dapsone-resistant My cobacterium leprae; and 2, to identify risk factors associated with the occurrence of dapsone-resistant M. leprae.
Materials and methods
The denominator chosen for the study was all LL and BL cases on the treatment register maintained by the Department of Epidemiology and Leprosy Control of 0305-75 1 8/83/054185+08 $01 .00 © British Leprosy Relief Association this institution at the end of December 1977, who resided within the control area. Every patient in the denominator was clinically examined by a medical officer, and skin smears were taken fr om 4 routine sites as well as fr om other sites at which there was evidence of activity.
Patients with a BI � 2 + at any one site were biopsied, preferably from the site with the highest index (avoiding the face). In order not to underestimate the number of patients harbouring dapsone-resistant M. leprae, biopsy was per fo rmed on all patients with a BI � 2 + , and not only on those showing evidence of active disease, as in the studies reported to date. I -1 3 It must be emphasized that those biopsied included patients improving on dapsone monotherapy, who would not ordinarily be suspected of harbouring dapsone-resistant M. leprae. Biopsies were usually taken in the field and transferred to the base laboratory on wet ice fo r mouse fo ot-pad studies, which were performed by methods already described. 14 , 1 5
The patients whose M. leprae fa iled to grow even in untreated mice, and those in whom the test did not detect resistant M. leprae, were rescreened and biopsied again if eligible.
Results and interpretation
All 1580 registered LL and BL patients residing within the area were enumerated in December 1977. The screening began in March 1978, and the activities undertaken during the next 3 years are summarized in Table 1 . Of the total, 143 1 patients were screened in the first year, fo rming a cohort that was subjected to annual screening, and biopsied when eligible.
In the first year 149 patients evaded screening. A 10% random sample of these patients were subsequently screened, and none was fo und eligible fo r biopsy. The 149 patients were therefore not included in any subsequent procedures or analysis.
As shown in Table 2 , 9 patients among the 143 1 screened had been shown earlier by mouse inoculation to harbour dapsone-resistant M. leprae. Table 2 also shows the number of patients fo und eligible fo r biopsy (BI � 2 + ) during each year of the study, and the number of patients subjected to biopsy. The large proportion of biopsies done during the third year of survey did not reflect an increase in the number of patients attaining eligibility for biopsy during that year, but resulted from an improved operational capacity for handling biopsy specimens. A total of 188 patients were fo und eligible for biopsy, of whom 142 have thus far been subjected to the procedure.
The results of biopsy and mouse inoculation are presented in Table 3 . Of the 188 patients eligible, 46 escaped biopsy for a variety of reasons. Of the 142 mouse fo ot-pad studies carried out, the results of 17 are still not available. In 26 studies the inoculated M. leprae fa iled to multiply in both control and dapsone-treated mice. Dapsone-resistant M. leprae were detected in 89 studies. The resistant M. leprae in 81 of these studies manifested resistance to the highest concentration of dapsone used (0'01 g%). 10 studies did not detect any dapsone-resistant M. leprae. It is of great interest to note that an eleventh study, which on one occasion did not detect dapsone-resistant M. leprae, was repeated on the same patient after a period of 12 months. On the second occasion, dapsone-resistant M. leprae were detected, that manifested resistance to the highest concentration of dapsone used.
Thus, of the 188 patients eligible fo r biopsy and mouse inoculation, the results of mouse fo ot-pad studies have so far been obtained fo r only 99. Because 89 patients for whom no results are available comprise so large a fr action of the total, it is necessary to make some assumptions regarding them, in order to estimate the number of patients harbouring dapsone-resistant M. leprae. It appears reason able to assume that among the 46 patients not subjected to biopsy and the 17 for whom results are awaited, the proportion who harbour dapsone-resistant M. leprae is the same as among those for whom results are available. The 26 patients whose organisms fa iled to multiply in control mice are problematic, however. It could be argued that these patients harbour no dapsone-resistant M. leprae, because such a large proportion of the organisms fr om these patients had been killed during dapsone treatment that no organisms grew even in untreated mice. However, it is possible that viable dapsone-resistant M. leprae were present, although the inoculum contained too few to produce growth in the mouse fo ot-pad. To allow fo r this uncertainty, a separate estimate of the total number of patients harbouring dapsone-resistant M. leprae has been made for each of the alternative possibilities.
It has already been pointed out that some patients who showed improvement on dapsone mono therapy were biopsied only because they had a BI � 2 +; these patients would not ordinarily have been suspected of harbouring dapsone-resis tant M. leprae. They differ markedly fr om the rest of the patients biopsied, in showing a decrease in BI in successive smears at the time of biopsy. Until the significance of this difference is more fu lly understood, it appears important to maintain the distinction between this group of patients and the rest. Therefore, the 188 patients eligible for biopsy have been divided in 2 groups: 142 who showed an increase in BI in successive smears at the time of biopsy; and 46 who showed a decrease in BI. Table 4 shows the estimation of the total numbers of patients harbouring It appears reasonable to assume that the true figure must fa ll somewhere between these two estimates.
Discussion
As reported earlier,1 5 the crude estimate of the prevalence of dapsone-resistant leprosy in Gudiyatham Taluk after the first year of this study was 23 per lOOO. This may be explained partly by our earlier inability to test in mice the M. leprae of all the patients eligible for biopsy during a given year, and partly by the fact that biopsy during the first year was done only on patients who were deteriorating, by smear and clinical criteria. The unexpected finding that patients who were improving on dapsone monotherapy were also shown by the mouse fo ot-pad test to harbour dapsone resistant M. leprae raises problems of interpretation. It would appear premature to make a decision on this until a detailed analysis of our data can be completed.
Analysis of risk factors has also been deferred. However, careful records have been kept of the treatment and progress of all the patients screened, from their date of diagnosis. An analysis of the prevalence of dapsone resistance, and its causation and consequences in the individual and in the community, will be undertaken in subsequent publications.
